Evidence map›Paper›PMID 34171067›Full record

ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie

Predictors of early and sustained virological response of viral hepatitis C.

Alice Elena Ghenea, Anca Marilena Ungureanu, Adriana Turculeanu, Mihaela Popescu, Mara Carsote, Maria Loredana Ţieranu, Eugen Nicolae Ţieranu, Corina Maria Vasile, Ramona Cioboată, Anca Loredana Udriştoiu and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Diagnostic and prognostic significance of hepatic steatosis in patients with chronic hepatitis C.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
  7. Gestational trophoblastic diseases - literature review and atypical case reports.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Alice Elena GheneaDepartment of Bacteriology-Virology-Parasitology, Department of Cardiology, University of Medicine and Pharmacy of Craiova, Romania; ancaungureanu65@yahoo.com, tieranueugen@gmail.com.
Anca Marilena Ungureanu
Adriana Turculeanu
Mihaela Popescu
Mara Carsote
Maria Loredana Ţieranu
Eugen Nicolae Ţieranu
Corina Maria Vasile
Ramona Cioboată
Anca Loredana Udriştoiu
Dragoş Ovidiu Alexandru
Alex Ioan Sălan
Andrei Ioan Drocaş
University of Medicine and Pharmacy of Craiova · ROCarol Davila University of Medicine and Pharmacy · ROUniversity of Craiova · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to complex interplay between host and viral factors, pathogenesis of chronic hepatitis C (CHC) is considered a challenging issue. Infection with hepatitis C virus (HCV) is not confined only to liver but can induce disturbances in many other organs and systems. Our primary aim for this study was to evaluate biological response rates and sustained virological response (SVR) in patients diagnosed with CHC, treated with Interferon-alpha (IFN-α), Pegylated (PEG)-IFN-α2a or -α2b plus Ribavirin. The second aim of the study was the identification of predictive factors for a favorable response to antiviral therapy in patients diagnosed with CHC. We enrolled in this study 210 patients diagnosed with CHC who have accomplished all inclusion and exclusion criteria, treated with PEG-IFN plus Ribavirin. Patients' recovery progress has been evaluated by determining: age, gender; biochemical tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST); serological assays - detect anti-HCV antibody and molecular assays - detect, quantify and/or characterize hepatitis C viral load (ribonucleic acid) (HCV-RNA); liver histopathological (HP) examination. According to their response to treatment, they were classified into responders (n=145) and non-responders (n=65). Liver biopsies were histopathologically evaluated for necroinflammatory grade and fibrosis stage according to the modified Ishak and Metavir scoring systems for chronic hepatitis. Demographic, laboratory, and HP results were introduced in statistical analysis. These parameters were included in area under curve (AUC) analysis in order to estimate their degree of influence on getting early virological response (EVR) and SVR. Our study demonstrates that factors connected to treatment failure in CHC are linked to older age, high hepatitis C viral load, and impaired glucose tolerance at beginning of treatment [high fasting glucose and insulin, high homeostatic model assessment of insulin resistance (HOMA-IR) index] and also to liver histology features (high fibrosis score, liver steatosis, iron infiltration, and more or less high necroinflammatory activity). Analyzing results of our study shows that HOMA-IR index, serum insulin levels, baseline HCV-RNA, baseline mean blood glucose and HP score like Ishak fibrosis score, steatosis score and liver iron score may have a predictive value for obtaining an EVR in patients diagnosed with CHC.

Indexed as

Hepatitis CHepatitis C, ChronicAgedAntiviral AgentsDrug Therapy, CombinationHepacivirusHumansInterferon alpha-2Polyethylene GlycolsRecombinant ProteinsRibavirinViral LoadAntiviral AgentsInterferon alpha-2Polyethylene GlycolsRecombinant ProteinsRibavirin

Identifiers

PMID34171067
PMCPMC8343650
OpenAlexW3174802196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.